LENZ Therapeutics grants Arrotex exclusive rights to market VIZZ for presbyopia in Australia and New Zealand
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $15.00M | N/A | N/A | N/A |
| Cost of Revenue | $58.00K | N/A | N/A | $734.00K | $121.00K | N/A |
| Gross Profit | $-58.00K | N/A | $15.00M | $-734.00K | $-121.00K | N/A |
| Gross Margin | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $58.55M | $72.43M | $25.48M | $59.71M | $13.38M | $29.00K |
| Operating Income | $-58.61M | $-72.43M | $-10.48M | $-60.44M | $-13.50M | $-29.00K |
| Operating Margin | 0.00% | 0.00% | -69.89% | 0.00% | 0.00% | 0.00% |
| Net Income | $-49.77M | $-69.97M | $-10.81M | $-70.76M | $-68.37M | $-109.00K |
| Net Margin | 0.00% | 0.00% | -72.07% | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-2.34 | $-15.30 | $-12.89 | $-8.54 | $-8.24 | $-0.01 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |